Skip to content
2000
Volume 14, Issue 17
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

A tremendous research on Poly (ADP-ribose) polymerase (PARP) pertaining to cancer and ischemia is in very rapid progress. PARP’s are a specific class of enzymes that repairs the damaged DNA. Recent findings suggest also that PARP-1 is the most abundantly expressed nuclear enzyme which involves in various therapeutic areas like inflammation, stroke, cardiac ischemia, cancer and diabetes. The current review describes the overview on clinical candidates of PARP1 and its current status in clinical trials. This paper also covers identification of potent PARP1 inhibitors using structure and ligand based pharmacophore models. Finally 36 potential hits were identified from the virtual screening of pharmacophore models and screened for PARP1 activity. 15 actives were identified as potent PARP1 inhibitors and further optimization of these analogues are in progress.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026614666140929152123
2014-09-01
2025-03-16
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026614666140929152123
Loading

  • Article Type:
    Research Article
Keyword(s): Cancer; docking; glide; PARP1; pharmacophore; virtual screening
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test